ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / FBLG / options
ENVB (34) APRE (40) XCUR (32) BGMS (38) ⌘ Pro Terminal β†’

FibroBiologics Inc. (FBLG) Options Positioning, Max Pain & Unusual Sweeps

$0.92 -1.06% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

FibroBiologics Inc. (FBLG) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $6.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FBLG Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.92 (-1.06% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FBLG ranks #582 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does FBLG compare to ENVB and APRE in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $6.4M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FBLG?
β–Ό

Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $46.6M in revenue (+21.2% YoY), -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.92 (-0.38%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (8)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$10 Bull$1 Base$1 Bear
πŸ“¬ FREE FBLG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for FBLG)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY FBLG SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)

FRED Regime Γ— Technicals: 3% of 52W Range β€’ RSI-14 at 36.6 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
44
Grade D$0.96-4.2% Next Q
Q2 (-2Q)
41
Grade D$0.92+1.1% Next Q
Q3 (-1Q)
39
Grade E$0.93-1.1% Next Q
Current
36
Grade D-$0.92-8.3% Hist 90D Ξ±
Trajectory: D (44) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a FBLG Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While FBLG currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.29) and Max Pain ($0.97) forces dealer call-delta covering toward $10.08.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FBLGβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œFBLG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (FBLG)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for FBLG.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FBLG)

  • βœ“Walkthrough of FBLG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
FBLG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.93H $0.93L $0.92C $0.92VOL 20.7K
RES: $2.91SUP: $0.92SMA50: $1.29SMA200: $2.32
$7.76$5.82$3.89$1.95$0.02RES $2.91SUP $0.92$0.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FBLG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ FBLG Butterfly Map β†’ + Track FBLG β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +21.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FBLG today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for FBLG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FBLG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FBLG)

Health Care Rank #582 of 1015 βš”οΈ ENVB vs FBLG Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (FBLG vs. ENVB, APRE, XCUR, BGMS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, FibroBiologics Inc. (FBLG) ranks #582 by composite RQD confidence (36/100, grade D-) and #924 by equity capitalization ($6.3M). Within this direct 5-issuer industry benchmark cohort, FBLG leads on earnings valuation at N/A trailing P/E, while FBLG leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with FBLG at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FBLG ACTIVE
FibroBiologics Inc.
D- 36/100 β€” β€” -35.0% -1.06% $6.3M Benchmark Subject
ENVB
Enveric Biosciences Inc.
E 34/100 β€” β€” -35.0% +1.40% $6.4M /envb-vs-fblg β†’
APRE
Aprea Therapeutics Inc.
D- 40/100 β€” β€” -35.0% +1.32% $6.1M /apre-vs-fblg β†’
XCUR
Exicure Inc.
E 32/100 β€” β€” -35.0% +0.99% $6.6M /xcur-vs-fblg β†’
BGMS
Bio Green Med Solution Inc.
D- 38/100 β€” β€” -35.0% 0.00% $6.0M /bgms-vs-fblg β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001958777 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), FibroBiologics Inc. (FBLG) reported GAAP revenue of $46.6M (+21.2% vs. FY2024 revenue of $38.5M , and +87.3% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$16.4M, and free cash flow of -$16.7M (-37.8% YoY). On the balance sheet, FBLG closed FY2025 with $9.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $46.6M -$18.6M -$16.4M -$16.7M $9.6M β€”
FY2024 (FY) 2024-12-31 $38.5M -$11.2M -$11.9M -$12.1M $16.4M β€”
FY2023 (FY) 2023-12-31 $24.9M -$16.5M -$6.4M -$6.4M β€” β€”

3. FBLG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FBLG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, FibroBiologics Inc. (NASDAQ: FBLG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.92 (-1.06% 1D, market cap $6.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FBLG ranks #582 in composite RQD confidence.

How does FBLG compare to ENVB and APRE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FBLG carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, ENVB (Enveric Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $6.4M) and APRE (Aprea Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $6.1M). Among the 5-stock peer group, FBLG leads on earnings multiple (N/A) while FBLG leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FBLG?

Per FBLG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001958777), FibroBiologics Inc. generated $46.6M in revenue (+21.2% YoY), -$18.6M in net income, and -$16.7M in free cash flow against $9.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FBLG trading relative to its 50-day, 200-day, and 52-week technical levels?

FBLG last traded at $0.92 (-1.06% on volume of 42,420 shares), positioning the stock -28.68% below its 50-day simple moving average ($1.29) and -60.34% below its 200-day simple moving average ($2.32). Across its 52-week range of $0.62 to $9.60, FBLG sits at the 3.3% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.04).

Direct Sub-Reports: FBLG RQD Cockpit FBLG 12M Forecast FBLG Earnings & Move FBLG Dividends & DRIP FBLG Insiders & 13F FBLG Whale Options FBLG Profit Sankey FBLG News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

FBLG β€” FibroBiologics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

FibroBiologics Inc. (FBLG) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.92 (-1.06% 1D, market capitalization $6.3M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (FBLG) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. β€” for specific products, customers, or the mechanism by which the company makes money.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), FibroBiologics Inc. (FBLG) reported $46.6M in annual revenue (up from $38.5M in FY2024, +21.2% YoY) and -$18.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.9M revenue, -$16.5M net income) through FY2025, FBLG scaled operating cash flow to -$16.4M and free cash flow to -$16.7M, backed by $9.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.62 – $9.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” for upstream/downstream dependencies or 2nd-order bottlenecks.

  • Key Question #1: Can FBLG sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $46.6M and free cash flow of -$16.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FBLG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FBLG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for FibroBiologics Inc. (FBLG) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to FBLG Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FBLG Bull vs. Bear Conversation Board β€” What's Your Call at $0.92?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FBLG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FBLG:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER β€’ Swing & Catalyst Trader πŸ‚ BULLISH 🎯 Target: $1.08 (+16.1%)
πŸ“Œ Pinned Debate

The Roarable RQD rating places Forensic Balance Sheet and Macro Regime Fit at 10/20 each, and the Altman Z-Score of 2.5 and Debt/Equity

Picked up a starter position in FBLG in my $100K Virtual Cash book at $0.93. The Roarable RQD rating places Forensic Balance Sheet and Macro Regime Fit at 10/20 each, and the Altman Z-Score of 2.5 and Debt/Equity of 0.5 are not in distress territory on those measures.. Trading inside a $0.62–$9.60 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader πŸ‚ BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $0.93 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.73 (-21.5%)
Spot @ $0.93

Operating income was -$16.6M in FY 2025 against $4.9M of reported cash, with ROIC at -35% and FCF yield at 0%.

Operating income was -$16.6M in FY 2025 against $4.9M of reported cash, with ROIC at -35% and FCF yield at 0%.. Look at the math on FBLG: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.82 before getting long.

LIVE TAPE